Učitavanje...
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients...
Spremljeno u:
| Izdano u: | Mult Scler Relat Disord |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier B.V.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7366111/ https://ncbi.nlm.nih.gov/pubmed/32711297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102402 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|